📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: XOMA

1.1 - Company Overview

XOMA Logo

XOMA

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of biotech royalty aggregation through acquiring economic rights to future milestone and royalty payments from pre-commercial clinical candidates and commercial therapies, supported by a royalty portfolio of licenses; also provider of antibody discovery and development via a phage display platform, with developing assets including ebopiprant and an anti-prolactin antibody.

Products and services

  • Phage Display Platform: Proprietary platform that utilizes phage display, library construction, and technologies for antibody humanization and enhancement, enabling discovery and development of optimized therapeutic antibodies
  • Royalty Portfolio: License-based collection offering rights to future potential royalty and milestone payments from drug candidates developed by other companies
  • XOMA Royalty: Economics-based aggregator that acquires economic rights to future milestone and royalty payments from pre-commercial clinical candidates and commercial therapies

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to XOMA

HighTide Therapeutics Logo

HighTide Therapeutics

HQ: China Website
  • Description: Provider of global clinical-stage biopharmaceutical drug development, centered on HTD1801, a candidate targeting NASH, type 2 diabetes (T2DM), severe hypertriglyceridemia (SHTG), primary sclerosing cholangitis (PSC), and primary biliary cholangitis (PBC). Conducts multi-regional clinical trials, including a Phase 2b study for NASH and a Phase 3 study for T2DM.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full HighTide Therapeutics company profile →
Rare Thyroid Therapeutics Logo

Rare Thyroid Therapeutics

HQ: Sweden Website
  • Description: Provider of late-stage orphan drug development.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Rare Thyroid Therapeutics company profile →
NGM Bio Logo

NGM Bio

HQ: United States Website
  • Description: Provider of biotherapeutic drug discovery focused on the gastrointestinal endocrine system, developing: NGM707 (ILT2/ILT4 antagonist), NGM831 (ILT3 antagonist), NGM438 (LAIR1 antagonist) for advanced solid tumors; NGM120 (GFRAL antagonist) for advanced solid tumors and cachexia; NGM621 (anti-Complement C3) for geographic atrophy; aldafermin (FGF19 analog) for NASH F4 and primary sclerosing cholangitis.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full NGM Bio company profile →
Alnara Pharmaceuticals Logo

Alnara Pharmaceuticals

HQ: United States Website
  • Description: Provider of orally delivered protein therapeutics for metabolic diseases, developing GI-targeted protein therapies designed to act in the gastrointestinal tract without being absorbed into the bloodstream.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Alnara Pharmaceuticals company profile →
Calliditas Therapeutics Logo

Calliditas Therapeutics

HQ: Sweden Website
  • Description: Provider of specialty pharmaceuticals for unmet medical needs in niche indications, including TARPEYO (delayed-release budesonide for renal diseases), Kinpeygo (renal and hepatic diseases), NEFECON (candidate for primary IgA nephropathy), and Setanaxib (NOX1/4 inhibitor in trials for PBC and head & neck cancer), plus pipeline development for orphan renal/hepatic diseases and strategic partnerships for development and commercialization.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Calliditas Therapeutics company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for XOMA

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to XOMA

2.2 - Growth funds investing in similar companies to XOMA

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for XOMA

4.2 - Public trading comparable groups for XOMA

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to XOMA

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About XOMA

What does XOMA do?

XOMA is a provider of biotech royalty aggregation through acquiring economic rights to future milestone and royalty payments from pre-commercial clinical candidates and commercial therapies, supported by a royalty portfolio of licenses; also provider of antibody discovery and development via a phage display platform, with developing assets including ebopiprant and an anti-prolactin antibody.

Who are XOMA's competitors?

XOMA's competitors and similar companies include HighTide Therapeutics, Rare Thyroid Therapeutics, NGM Bio, Alnara Pharmaceuticals, and Calliditas Therapeutics.

Where is XOMA headquartered?

XOMA is headquartered in United States.

How many employees does XOMA have?

XOMA has 1,000 employees 🔒.

When was XOMA founded?

XOMA was founded in 2010 🔒.

What sector and industry vertical is XOMA in?

XOMA is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for XOMA

Who are the top strategic acquirers in XOMA's sector and industry

Top strategic M&A buyers and acquirers in XOMA's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for XOMA?

Top strategic M&A buyers groups and sectors for XOMA include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in XOMA's sector and industry vertical

Which are the top PE firms investing in XOMA's sector and industry vertical?

Top PE firms investing in XOMA's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in XOMA's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in XOMA's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in XOMA's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to XOMA include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in XOMA's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for XOMA?

The key public trading comparables and valuation benchmarks for XOMA include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for XOMA for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for XOMA with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in XOMA's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for XOMA with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in XOMA's' sector and industry vertical?

Access recent funding rounds and capital raises in XOMA's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for XOMA